ValuEngine cut shares of Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday.

A number of other equities analysts also recently weighed in on GALT. HC Wainwright upped their target price on Galectin Therapeutics Inc. Common Stock to $12.00 and gave the company a buy rating in a report on Tuesday, May 15th. BidaskClub upgraded Galectin Therapeutics Inc. Common Stock from a buy rating to a strong-buy rating in a report on Friday, June 15th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $6.94.

Shares of Galectin Therapeutics Inc. Common Stock remained flat at $$4.50 during trading hours on Wednesday, according to MarketBeat Ratings. The stock had a trading volume of 345,530 shares, compared to its average volume of 401,154. The firm has a market cap of $194.61 million, a P/E ratio of -9.18 and a beta of 2.29. Galectin Therapeutics Inc. Common Stock has a one year low of $1.28 and a one year high of $9.49.

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) last issued its earnings results on Friday, May 11th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. analysts anticipate that Galectin Therapeutics Inc. Common Stock will post -0.46 EPS for the current year.

In related news, Director James C. Czirr sold 60,000 shares of the stock in a transaction that occurred on Monday, June 18th. The stock was sold at an average price of $9.06, for a total value of $543,600.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Fund L.P. 10X sold 50,000 shares of the stock in a transaction that occurred on Monday, June 4th. The stock was sold at an average price of $5.12, for a total value of $256,000.00. The disclosure for this sale can be found here. Insiders sold 1,743,263 shares of company stock worth $11,905,122 in the last 90 days. 38.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in GALT. D.A. Davidson & CO. increased its holdings in Galectin Therapeutics Inc. Common Stock by 6.3% in the first quarter. D.A. Davidson & CO. now owns 731,300 shares of the company’s stock worth $3,466,000 after buying an additional 43,147 shares during the last quarter. Benchmark Capital Advisors grew its holdings in Galectin Therapeutics Inc. Common Stock by 19.7% during the first quarter. Benchmark Capital Advisors now owns 221,700 shares of the company’s stock valued at $1,051,000 after purchasing an additional 36,500 shares during the last quarter. Tibra Equities Europe Ltd acquired a new position in Galectin Therapeutics Inc. Common Stock during the first quarter valued at approximately $301,000. A.R.T. Advisors LLC grew its holdings in Galectin Therapeutics Inc. Common Stock by 60.2% during the first quarter. A.R.T. Advisors LLC now owns 57,775 shares of the company’s stock valued at $273,000 after purchasing an additional 21,704 shares during the last quarter. Finally, LPL Financial LLC acquired a new position in Galectin Therapeutics Inc. Common Stock during the first quarter valued at approximately $112,000. Hedge funds and other institutional investors own 12.32% of the company’s stock.

Galectin Therapeutics Inc. Common Stock Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

See Also: How to Use the New Google Finance Tool

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Galectin Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.